Integrative genomics analysis identifies candidate drivers at 3q26-29 amplicon in squamous cell carcinoma of the lung

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5580-5590

  Wang, Jing ^a   Qian, Jun ^a   Hoeksema, Megan D ^a   Zou, Yong ^a   Espinosa, Allan V ^a   Rahman, S M Jamshedur ^a   Zhang, Bing ^a   Massion, Pierre P ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Veterans Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN DCUN1D1; PROTEIN DVL3; PROTEIN SENP2; PROTEIN UBXN7; RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AMPLICON; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GENETICS; CELL VIABILITY; CHROMOSOME 3Q; CHROMOSOME 3Q26 29; COHORT ANALYSIS; CONSENSUS SEQUENCE; DCUN1D1 GENE; DOWN REGULATION; DVL3 GENE; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE SILENCING; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; LUNG CARCINOGENESIS; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SENP2 GENE; TREATMENT RESPONSE; TUMOR GENE; UBXN7 GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 3; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENE REGULATORY NETWORKS; GENOMICS; HUMANS; LUNG NEOPLASMS; ONCOGENES; TRANSCRIPTOME;

EID: 84886434321     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0594     Document Type: Article

References (52)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Strauss GM. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances. Hematol Oncol Clin North Am 2005;19:263-81.
3. Yakut T, Schulten HJ, Demir A, Frank D, Danner B, Egeli U, et al. Assessment of molecular events in squamous and non-squamous cell lung carcinoma. Lung Cancer 2006;54:293-301.
4. Purdie KJ, Harwood CA, Gulati A, Chaplin T, Lambert SR, Cerio R, et al. Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. J Invest Dermatol 2009;129:1562-8.
5. Qian J, Massion PP. Role of chromosome 3q amplification in lung cancer. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer. 2008;3:212-5.
6. Levin NA, Brzoska PM, Warnock ML, Gray JW, Christman MF. Identification of novel regions of altered DNA copy number in small cell lung tumors. Genes Chromosomes Cancer 1995;13:175-85.
7. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004;170: 1088-94.
8. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002;62:3636-40.
9. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-42.
10. Sarkaria I, O-charoenrat P, Talbot SG, Reddy PG, Ngai I, Maghami E, et al. Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. Cancer Res 2006;66:9437-44.
11. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003;63: 7113-21.
12. Brass N, Heckel D, Sahin U, Pfreundschuh M, Sybrecht GW, Meese E. Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet 1997;6:33-9.
13. Choi YW, Choi JS, Zheng LT, Lim YJ, Yoon HK, Kim YH, et al. Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung. Lung Cancer 2007;55:43-51.
14. Racz A, Brass N, Heckel D, Pahl S, Remberger K, Meese E. Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma. Eur J Cancer 1999;35:641-6.
15. Yokoi S, Yasui K, Iizasa T, Imoto I, Fujisawa T, Inazawa J. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin Cancer Res 2003;9:4705-13.
16. Fields AP, Justilien V. The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer. Adv Enzyme Regul 2010;50: 190-200.
17. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, LohseCM, et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005;65:8905-11.
18. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 2009;9:237.
19. Xu C, Liu Y, Wang P, Fan W, Rue TC, Upton MP, et al. Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival. Mol Cancer 2010;9:143.
20. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.
21. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
22. Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008;14:7397-404.
23. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66:7466-72.
24. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010;16:4864-75.
25. Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009;15: 284-90.
26. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010;28: 4417-24.
27. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
28. Aerts S, Lambrechts D, Maity S, Van Loo P, Coessens B, De Smet F, et al. Gene prioritization through genomic data fusion. Nat Biotechnol 2006;24:537-44.
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B (Methodological) 1995;57:289-300.
30. Zhang B, Shi Z, Duncan DT, Prodduturi N, Marnett LJ, Liebler DC. Relating protein adduction to gene expression changes: a systems approach. Mol Biosyst 2011;7:2118-27.
31. Shi M, Beauchamp RD, Zhang B. A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients. PLoS ONE 2012;7:e41292.
32. Kohler S, Bauer S, Horn D, Robinson PN. Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 2008;82: 949-58.
33. Qian J, Zou Y, Rahman JS, Lu B, Massion PP. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther 2009;8:101-9.
34. Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H, et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 2013;19: 560-70.
35. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, et al. An integrated genomic analysis of lung cancer reveals loss ofDUSP4 in EGFR-mutant tumors. Oncogene 2009;28:2773-83.
36. Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
37. Redon R, Muller D, Caulee K, Wanherdrick K, Abecassis J, du Manoir S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res 2001;61: 4122-9.
38. Umayahara K, Numa F, Suehiro Y, Sakata A, Nawata S, Ogata H, et al. Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chromosomes Cancer 2002;33:98-102.
39. Kim AY, Bommelje CC, Lee BE, Yonekawa Y, Choi L, Morris LG, et al. SCCRO (DCUN1D1) is an essential component of the E3 complex for neddylation. J Biol Chem 2008;283:33211-20.
40. Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci U S A 2010;107:2183-8.
41. Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev 2004;18:2046-59.
42. Bawa-Khalfe T, Yeh ET. SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer 2010;1:748-52.
43. Jiang M, Chiu SY, Hsu W. SUMO-specific protease 2 in Mdm2-mediated regulation of p53. Cell Death Differ 2011;18:1005-15.
44. Carter S, Vousden KH. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008;7:2519-28.
45. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004;118:83-97.
46. Wallingford JB, Habas R. The developmental biology of Dishevelled: an enigmatic protein governing cell fate and cell polarity. Development 2005;132:4421-36.
47. Angers S, Thorpe CJ, Biechele TL, Goldenberg SJ, Zheng N, MacCoss MJ, et al. The KLHL12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting Dishevelled for degradation. Nat Cell Biol 2006;8:348-57.
48. Shi I, Hashemi Sadraei N, Duan ZH, Shi T. Aberrant signaling pathways in squamous cell lung carcinoma. Cancer Inform 2011;10:273-85.
49. Lee EH, Chari R, Lam A, Ng RT, Yee J, English J, et al. Disruption of the non-canonical WNT pathway in lung squamous cell carcinoma. Clin Med Oncol 2008;2008:169-79.
50. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003;22:7218-21.
51. Shen HJ, Zhu HY, Yang C, Ji F. SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. Asian Pac J Cancer Prev 2012;13:3583-7.
52. Kadoya T, Yamamoto H, Suzuki T, Yukita A, Fukui A, Michiue T, et al. Desumoylation activity of Axam, a novel Axin-binding protein, is involved in downregulation of beta-catenin. Mol Cell Biol 2002;22: 3803-19.